Equities Analysts Set Expectations for Cingulate Q4 Earnings

Cingulate Inc. (NASDAQ:CING) – Equities researchers at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for shares of Cingulate in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($1.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. HC Wainwright also issued estimates for Cingulate’s Q1 2025 earnings at ($1.05) EPS, Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.58) EPS and Q4 2025 earnings at ($0.56) EPS.

Cingulate (NASDAQ:CING) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($2.22) by $0.39.

A number of other research firms have also recently issued reports on CING. Roth Mkm started coverage on Cingulate in a report on Friday, January 10th. They set a “buy” rating and a $12.00 target price for the company. Maxim Group upgraded Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Roth Capital upgraded Cingulate to a “strong-buy” rating in a report on Friday, January 10th.

Cingulate Stock Performance

CING opened at $4.56 on Monday. Cingulate has a 12 month low of $1.80 and a 12 month high of $20.83. The company has a fifty day simple moving average of $4.58 and a 200 day simple moving average of $4.65.

Hedge Funds Weigh In On Cingulate

A hedge fund recently bought a new stake in Cingulate stock. Jane Street Group LLC acquired a new position in Cingulate Inc. (NASDAQ:CING) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 21,031 shares of the company’s stock, valued at approximately $106,000. Jane Street Group LLC owned about 0.66% of Cingulate as of its most recent SEC filing. Institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.